By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Cerenis Therapeutics, Inc. 

900 Victors Way
Suite 280
Ann Arbor  Michigan  48108  U.S.A.
Phone: 734-769-1110 Fax: 734-769-1132



Company News
Cerenis Therapeutics, Inc. Announces The Appointment Of A New Chief Medical Officer And New Board Members 2/9/2015 11:00:36 AM
Cerenis Therapeutics, Inc. Receives European Medicines Agency Orphan Drug Designations For CER-001 For The Treatment Of ApoA-I And ABCA-1 Deficiencies 9/3/2014 12:44:17 PM
Cerenis Therapeutics, Inc. Appoints Dr. Richard C. Pasternak As Chairman 9/3/2014 10:59:52 AM
Cerenis Therapeutics, Inc. Reports Two Positive Phase II Studies For HDL Mimetic CER-001 At EAS 6/2/2014 9:09:13 AM
Cerenis Therapeutics, Inc.'s Cholesterol Drug CER-001 Fails In Mid-Stage Trial 1/2/2014 6:57:02 AM
Cerenis Therapeutics, Inc. Selected as a 2012 Red Herring Top 100 Europe 4/27/2012 11:47:41 AM
The Board of Cerenis Therapeutics, Inc. Appoints Dr. Richard C. Pasternak as Non Executive Director 11/22/2011 10:47:23 AM
Cerenis Therapeutics, Inc. Appoints John F. Paolini as Chief Medical Officer 11/22/2011 8:44:03 AM
Drug Veterans Court French Upstart, Cerenis Therapeutics, Inc. With Plaque Attack Remedy 4/8/2011 6:35:16 AM
Cerenis Therapeutics, Inc. Initiates Phase 2 Study of Lead Product Candidate, CER-001, in Patients with Acute Coronary Syndrome 3/15/2011 10:37:20 AM